azd5213
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2010 (NCT01121302)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorANTAGONIST
HRH3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd5213
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01928381 | Phase 2 | Nov 1, 2013 | AstraZeneca |
| NCT01904773 | Phase 2 | Aug 1, 2013 | AstraZeneca |
| NCT01548287 | Phase 2 | Apr 1, 2012 | AstraZeneca, IQVIA |
| NCT01335451 | Phase 1 | Apr 1, 2011 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT01194986 | Phase 1 | Nov 1, 2010 | AstraZeneca, IQVIA |
| NCT01171105 | Phase 1 | Jul 1, 2010 | AstraZeneca, IQVIA |
| NCT01121302 | Phase 1 | May 1, 2010 | AstraZeneca, IQVIA |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 7 | 7 | 2 | 2010 |
| IQVIA | For profit | 4 | 0 | 2 | 2010 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1